FUSOGENIC LIPOSOME FOR THE TREATMENT OF FUNGAL MENINGITIS: AN OVERVIEW
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i12.26852Keywords:
Fungal meningitis, Nanotechnology, Liposomes, Fusogenic liposomesAbstract
Fungal meningitis is an infection which is caused by fungus which spreads through the blood to the spinal cord. People with weakened immunity get this disease easily like persons with AIDs, etc. To make sure the disease is fungal meningitis, a sample is taken from the cerebrospinal fluid and it is sent to the laboratory. Usually, fungal meningitis is not mediated from person to person, but it is caused when a fungi are inhaled from the surrounding and spread into the blood to the central nervous system. Normally medications such as vaccines, IV, and oral suspensions are given to the people for curing fungal meningitis. Commonly used drugs are Amphotericin B and fluconazole oral suspension. Amphotericin B is an antifungal, antiprotozoal, and hydrophobic drug. However, these drugs cannot give a directly as medication therapy for the patients, because it offers toxic effect and side effects, absorption rate is slower, and crossing the blood–brain barrier (BBB) is getting difficult. Adverse effects can be minimized with the application of nanotechnology. Therefore, in human medical services, the availability of molecular nanotechnology will provide rapid progress. Nanoparticle (NP) systems help to improve the solubility of poorly water-soluble drugs which has been explained using Noyes–Whitney equations. Nanoparticles offers several advantages as a drug delivery system, such as better drug bioavailability, reduction of dosing frequency enables them for the betterment of diseases, can cross the BBB, and it is very cost-effective. Types of NP include polymeric NP, carbon nanotubes, metallic structures, nanocrystals, and fusogenic liposomes. Fusogenic liposomes are a peculiar class of phospholipid vesicles. The fusogenic liposomes can deliver encapsulated NP into the targeted sites and also can cross the BBB. On comparing with cationic liposomes, fusogenic liposomes are more effective as well as rapid in the drug delivery.
Downloads
References
Honda H, Warren DK. Central nervous system infections: Meningitis and brain abscess. Infect Dis Clin North Am 2009;23:609-23.
Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Clin Pharmacokinet 2000;38:111-80.
Mohammed N, Rejinold NS, Mangalathillam S, Biswas R, Nair SV, Jayakumar R, et al. Fluconazole loaded chitin nanogels as a topical ocular drug delivery agent for corneal fungal infections. J Biomed Nanotechnol 2013;9:1521-31.
Walker R, Whittlesea C. Clinical Pharmacy and Therapeutics. 5th ed. London: Churchill Livingstone; 2011. p. 661.
Mendez-Vilas A. Science against microbial pathogens: Communicating current research and technological advances. Current 2011;2:1-691.
Porter RS, Kalpan JL. The Merck Manual of Diagnosis and Therapy. 19th ed. London: Merck and Co., Inc; 1930. p. 1321-2.
Nagavarma BV, Hemant KS, Ayaz A, Vasudha LS, Shivakumar HG. Different techniques for preparation of polymeric nanoparticles- a review. Asian J Pharm Clin Res 2012;5:16-23.
Chien S. Intracellular ATP delivery using highly fusogenic liposomes. In: Weissig V, editor. Liposomes: Methods and Protocols. Vol.1: Pharmaceutical Nanocarriers. New York: Springer; 2009. p. 377-91.
Ezhilarasi PN, Karthik P, hhanwal N, Anandharamakrishnan C. Nanoencapsulation techniques for food bioactive components: A review. Food Bioproc Technol 2012;6:628-47.
Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm 2010;385:113-42.
Olga S, Yan Y, Yajun W, Frank C. Shape-dependent cellular processing of polyelectrolyte capsules. ACS Nano 2013;7:522-30.
Ren WH, Chang J, Yan CH, Qian XM, Long LX, He B, et al. Development of transferrin functionalized poly(ethylene glycol)/ poly(lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma. J Mater Sci Mater Med 2010;21:2673-81.
Takeuchi K, Hayashi T, Kim YA, Fujisawa K, Endo M. The state-of-the-art science and applications of carbon nanotubes. Nano J Ifmo Ru 2014;5:15.
Mangalathillam S, Rejinold NS, Nair A, Lakshmanan VK, Nair SV, Jayakumar R, et al. Curcumin loaded chitin nanogels for skin cancer treatment via the transdermal route. Nanoscale 2012;4:239-50.
Singh SS, Roy A, Lee B, Banerjee I, Kumta PN. Synthesis, characterization, and in-vitro cytocompatibility of amorphous β-tri-calcium magnesium phosphate ceramics. Mater Sci Eng C Mater Biol Appl 2016;67:636-45.
Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: Finite networks of infinite capabilities. Angew Chem Int Ed Engl 2009;48:5418-29.
Nakanishi M, Mizuguchi H, Ashihara K, Senda T, Eguchi A, Watabe A, et al. Gene delivery systems using the Sendai virus. Mol Membr Biol 1999;16:123-7.
Yoshikawa T, Imazu S, Gao JQ, Hayashi K, Tsuda Y, Okada N, et al. Non-methylated cpG motif packaged into fusogenic liposomes enhance antigen-specific immunity in mice. Biol Pharm Bull 2006;29:105-9.
Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond) 2013;8:1509-28.
Wiener N, Lieb L. Medical Applications of Liposome. Oxford: Elsevier; 1998.
Kunisawa J, Masuda T, Katayama K, Yoshikawa T, Tsutsumi Y, Akashi M, et al. Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene release. J Control Release 2005;105:344-53.
Freise J, Magerstedt P. Liposomes as a Drug Carrier. Stuttgart: George ThiemeVerlag; 1986.
Ranade VV. Drug delivery systems 1. Site-specific drug delivery using liposomes as carriers. J Clin Pharmacol 1989;29:685-94.
Boomer JA, Qualls MM, Inerowicz HD, Haynes RH, Patri VS, Kim JM, et al. Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. Bioconjug Chem 2009;20:47-59.
Meers PR, Shangguan T, Cabral-Lilly D, Ahl P, Erukulla R, Janoff A. Modular Targeted Liposomal Delivery Systems. US: US Patent; 2006.
Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: Application to vaccine development. Adv Drug Deliv Rev 2001;52:177-86.
Yoshikaw T. Fusogenic liposomes and their suitability for gene delivery. Future Lipidol 2006;1:735-42.
Karanth H, Murthy RS. PH-sensitive liposomes – principle and application in cancer therapy. J Pharm Pharmacol 2007;59:469-83.
Shangguan T, Cabral-Lilly D, Purandare U, Godin N, Ahl P, Janoff A, et al. A novel N-acyl phosphatidylethanolamine-containing delivery vehicle for spermine-condensed plasmid DNA. Gene Ther 2000;7:769-83.
Cullis PR, Choi LS, Monck M, Bailey AL. Fusogenic Liposomes. US: US Patent; 2003.
Simões S, Moreira JN, Fonseca C, Düzgüneş N, de Lima MC. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 2004;56:947-65.
Li H, Nelson CE, Evans BC, Duvall CL. Delivery of intracellular-acting biologics in pro-apoptotic therapies. Curr Pharm Des 2011;17:293-319.
Csiszár A, Hersch N, Dieluweit S, Biehl R, Merkel R, Hoffmann B, et al. Novel fusogenic liposomes for fluorescent cell labeling and membrane modification. Bioconjug Chem 2010;21:537-43.
Mustata RC, Grigorescu A, Petrescu SM. Encapsulated cargo internalized by fusogenic liposomes partially overlaps the endoplasmic reticulum. J Cell Mol Med 2009;13:3110-21.
Jilsha G, Viswanad V. Nanosponges: A novel approach of drug delivery system. Int J Pharm Sci Rev Res 2013;19:119-23.
Karenbaxter A, Preston CL. Stockley’s Drug interaction. 10th ed. New York: Marcel Dekker; 2012. p. 210.
Grubber SM. Liposome Biophysics Therapeutics. New York: Marcel Dekker; 1987.
Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010;277:4814-27.
Vartholomeos P, Fruchard M, Ferreira A, Mavroidis C. MRI-guided nanorobotic systems for therapeutic and diagnostic applications. Annu Rev Biomed Eng 2011;13:157-84.
Michel V, Yoshiharu D, Karl-Heinz H, Michael H, Philip H, Przemyslaw K, et al. Terminology for bio related polymers and applications (IUPAC recommendations 2012. Pure Appl Chem 2012;84:377–410.
Brian PT, Kathryn W, Weiwei G, Daniel SK, Omid F, Daniel A, et al. Advances in drug delivery. Ann Rev Matr Res 2011;41:1-20.
Fuhr O, Dehnen S, Fenske D. Chalcogenide clusters of copper and silver from silyliatedchalcogenide sources. Chem Soc Rev 2013;42:1871-906.
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences. Suita, Osaka: Osaka University 1-6 Yamadaoka. p. 565-871.
Mok KW, Cullis PR. Structural and fusogenic properties of cationic liposomes in the presence of plasmid DNA. Biophys J 1997;73:2534-45.
Bencherif SA, Siegwart DJ, Srinivasan A, Horkay F, Hollinger JO, Washburn NR, et al. Nanostructured hybrid hydrogels prepared by a combination of atom transfer radical polymerization and free radical polymerization. Biomaterials 2009;30:5270-8.
Cui J, Ren B, Tong Y, Dai H, Zhang L. Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans. Virulence 2015;6:362-71.
Priyanka R, Bhattacharya S. A review on promising antibiotic therapy by novel delivery system. Asian J Pharm Clin Res 2018;11:5.
Chandran PK, Ulagan MP. Antimicrobial and anticancer activity of silver nanoparticles from edible mushroom. Asian J Pharm Clin Res 2017;10:3.
Kadian R. Nanoparticles: A promising drug delivery approach. Asian J Pharm Clin Res 2018;11:1.
Davis S. Drug delivery systems interdisciplinary. Sci Rev 2000;25:175.
Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: A review. Crit Rev Ther Drug Carrier Syst 2002;19:99-134.
Ringe K, Walz C, Sabel B. Nanoparticle drug delivery to the brain. In: Nalwa, HS, editor. Encylopedia of Nano Science and Nanotechnology. New York: American Scientific Publishers; 2004.
Tiwari KB, Rijal B, Ghimire P, Sharma AP. Acute bacterial meningitis in nepal. Nepal Med Coll J 2007;9:100-3.
Esta LP, Castanedapastor A, Navarrom G, Gcercia-Madero R, Lopez-Cano Gomez M, Ayud-fernandez M. Comparative studies of Staphylococcus aures and Coagulase negative staphylococci in adults. Rev Neurol 2009;48:2-6.
Perelshtein I, Applerot G, Perkas N, Guibert G, Mikhailov S, Gedanken A, et al. Sonochemical coating of silver nanoparticles on textile fabrics (nylon, polyester and cotton) and their antibacterial activity. Nanotechnology 2008;19:245705.
Bender AR, von Briesen H, Kreuter J, Duncan IB, Rübsamen- Waigmann H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/ macrophages in vitro. Antimicrob Agents Chemother 1996;40:1467-71.
Jahanshahi M, Babali Z. Protein nanoparticle: A unique system as drug delivery vehicles. Afr J Biotech 2008;7:4926.
Schroeder U, Sommerfeld P, Ulrich S, Sabel BA. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 1998;87:1305-7.
Christophe LJ, Allémann F, Jaeghere FD, Doelker E, Gurny R. Biodegradable nanoparticles-from sustained release formulations to improved site specific drug delivery. J Control Release 1996;39:339.
Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505-15.
Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20.
Mahapatro A, Singh DK. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines. J Nanobiotechnology 2011;9:55.
Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003;55:329-47.
Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans K, et al. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J Control Release 2014;190:607-23.
Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84.
Kanra G, Akan O, Ecevit Z, Ceyhan M, Seçmeer G. Microorganisms involved in acute bacterial meningitis in children and the role of haemophilus influenzae. Turk J Pediatr 1996;38:407-12.
Gray LD, Fedorko DP. Laboratory diagnosis of bacterial meningitis. Clin Microbiol Rev 1992;5:130-45.
Csiszár A, Csiszar A, Pinto JT, Gautam T, Kleusch C, Hoffmann B, et al. Resveratrol encapsulated in novel fusogenic liposomes activates nrf2 and attenuates oxidative stress in cerebromicrovascular endothelial cells from aged rats. J Gerontol A Biol Sci Med Sci 2015;70:303-13.
Mriouah J, Nesbitt RN, Pink D. Fusogenic liposome: A novel therapeutic strategy to efficiently target and destroy prostate cancer. Cancer 2014;2014:821.
Yoshikawa T, Imazu S, Gao JQ, Hayashi K, Tsuda Y, Okada N, et al. Non-methylated cpG motif packaged into fusogenic liposomes enhance antigen-specific immunity in mice. Biol Pharm Bull 2006;29:105-9.
Bartomeu Garcia C, Shi D, Webster TJ. Tat-functionalized liposomes for the treatment of meningitis: An in vitro study. Int J Nanomedicine 2017;12:3009-21.
Csiszár A, Hersch N, Dieluweit S, Biehl R, Merkel R, Hoffmann B, et al. Novel fusogenic liposomes for fluorescent cell labeling and membrane modification. Bioconjug Chem 2010;21:537-43.
Kleusch C, Hersch N, Hoffmann B, Merkel R, Csiszár A. Fluorescent lipids: Functional parts of fusogenic liposomes and tools for cell membrane labeling and visualization. Molecules 2012;17:1055-73.
Kube S, Hersch N, Naumovska E, Gensch T, Hendriks J, Franzen A, et al. Fusogenic liposomes as nanocarriers for the delivery of intracellular proteins. Langmuir 2017;33:1051-9.
Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-12.
Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: A single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994;86:754-60.
Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995;155:1093-8.
Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): A comparative review. J Clin Pharmacol 1998;38:583-92.
Scarcella A, Pasquariello MB, Giugliano B, Vendemmia M, de Lucia A. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17:146-8.
Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B, et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989;149:2533-6.
Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW. Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother 1998;42:1412-6.
Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: Current understanding of mechanisms of action. Antimicrob Agents Chemother 1990;34:183-8.
Brajtburg J, Powderly WG, Kobayashi GS, Medoff G. Amphotericin B: Delivery systems. Antimicrob Agents Chemother 1990;34:381-4.
Weber RS, Lopez-Berestein G. Treatment of invasive aspergillus sinusitis with liposomal-amphotericin B. Laryngoscope 1987;97:937-41.
Bellocchio S, Gaziano R, Bozza S, Rossi G, Montagnoli C, Perruccio K, et al. Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting toll-like receptor signalling from TLR-2 to TLR-4. J Antimicrob Chemother 2005;55:214-22.
Chang HI, Yeh MK. Clinical development of liposome-based drugs: Formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 2012;7:49-60.
Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 2013;65:36-48.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
